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doi:10.1016/j.ejvs.2008.12.017Abstract Objectives: Postconditioning of ischaemic tissue, via mechanical or pharmacolog-
ical manipulation, offers an exciting avenue towards amelioration of ischaemiaereperfusion
injury. Born from the concept of ischaemic preconditioning, postconditioning is advantageous
in that prior knowledge of the ischaemic insult is not required, and thus clinical translation
may be further reaching. This review explores the current evidence and controversies in both
animal and human studies and multiple organ systems.
Methods: A Medline search was conducted to identify English-language articles with ‘postcon-
ditioning’ as a keyword. Two independent researchers scrutinised the literature search for
potentially relevant articles. Reference lists from selected articles were manually searched
for further relevant articles.
Results and conclusions: Postconditioning has been shown to be successful in reducing ischae-
miaereperfusion injury in both animal models and clinical trials. Human studies are presently
limited to cardiac studies, but there is scope for research into other organ systems with poten-
tial beneficial effects, particularly within the field of vascular surgery where ischaemiaereper-
fusion occurs by nature of both e the disease and the intervention.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Postconditioning (PostC) is defined as repetitive cycles of
briefly interrupted reperfusion applied at the onset of
establishing reflow and has been shown to significantly
improve outcome following an episode of ischaemia.1 While
seemingly paradoxical that interrupting blood flow shouldord, MBChB. Tel.: þ44 113
@hotmail.com
ty for Vascular Surgery. Publisheimprove outcome, the concept of PostC has arisen from the
evolving understanding of ischaemiaereperfusion injury
(IRI). Success at re-vascularisation has highlighted the
detrimental impact of IRI in virtually every organ system in
the body. Ischaemia primes the endothelium to the subse-
quent reperfusion insult, and the endothelial dysfunction
thus induced is the harbinger of organ failure, despite
restoration of blood supply. IRI has proven to be extremely
challenging to protect against, because its aetiology is
multifactorial. A possible breakthrough came with thed by Elsevier Ltd. All rights reserved.
438 K.A. Mockford et al.concept of ischaemic preconditioning (IPC),2 whereby short
ischaemic episodes preceding the index ischaemia
conferred protection from the insult. The last 2 decades
have seen limited but successful use of this technique in
cardiology and transplant surgery.
In 1996, Na et al. described PostC when they applied 10-
min periods of intermittent reperfusion to cat myocardium
following a 20-min period of index ischaemia and showed
comparable benefit to IPC in reducing ventricular fibrilla-
tion.3 PostC, as a concept, originated from initial work done
in cardiac surgery where IRI-induced myocardial damage
was noted to be improved by cardioplegic strategies aimed
at slowly initiating reflow following a period of coronary
vessel occlusion.4,5 Zhao et al. re-ignited interest in PostC
by demonstrating, for the first time, a reduction in infarct
size using canine myocardium, an effect similar to that
produced by IPC.1
Recently, IRI protective strategies have shown successful
translation into vascular surgery for the first time. In 2007,
Ali et al. successfully used IPC in reducing myocardial
infarction by 22%, myocardial injury by 27% and renal
impairment by 23% in elective abdominal aortic aneurysm
repair.6 This was achieved by two cycles of intermittent
cross-clamping of one common iliac artery producing a 10-
min period of ischaemia, followed by a 10-min period of
reperfusion. Although PostC remains elusive from vascular
surgery thus far, effective cardioprotection has been
demonstrated in clinical practice.7 PostC has an exciting
potential advantage over its sister concept, IPC, in that
PostC addresses the significant limitations of IPC in vaso-
occlusive emergencies where precise information about the
timing of index ischaemia is not available.
This review examines the evidence from animal and
human studies for use of PostC in ameliorating IRI and its
potential for application in vascular surgery.
Methods
Two independent researchers reviewed the literature.
Using Medline, articles citing ‘reperfusion injury’, ‘pre-
conditioning’ and ‘postconditioning’ as keywords were
identified. Of these, 204 and 538 abstracts were retrieved
for preconditioning and reperfusion injury, respectively,
using core clinical journals, human studies, randomised
controlled studies (RCTs) and English language as filters. For
PostC, no filters were used, giving a total of 356 abstracts.
The abstracts were scrutinised for relevance to patho-
physiology, human and animal studies and clinical applica-
tion of PostC. Those not pertaining to IRI, IPC or PostC were
discarded. One hundred and forty articles were short listed
and analysed in detail, and 36 key papers were used for the
purposes of this review. Reference lists of relevant selected
articles were manually searched for further appropriate
articles and to ensure that no key papers were missed.
Mechanisms of PostC-induced protection
Although our understanding of the precise cellular signal-
ling events is still in evolution, similarities exist between
pre- and PostC despite the fundamental differences in the
timing of protection. The main theories of PostC-inducedprotection centre around the preservation of mitochondrial
integrity via regulation of the mitochondrial permeability
transition pore (mPTP), reduced sensitivity to the increased
intracellular calcium (Ca2þ) levels triggered by IRI, resto-
ration of redox balance and nitric oxide (NO)-mediated
vaso-relaxation.
Mitochondria are crucial in maintaining cellular function
and, therefore, mechanisms of protection must involve
mitochondrial survival. The mPTP is a protein pore on the
mitochondrial membrane that is formed in pathological
states. Opening of the mPTP allows small molecules (less
than 1500 Da) to enter the mitochondrial matrix, initiating
a cascade of events, including the release of apoptosis-
inducing factors (AIF), such as cytochrome c, which in turn
activate enzymes known as caspases, stimulating rupture of
the outer membrane, apoptosis and necrosis. Argaud et al.
found that inhibition of the mPTP opening by using specific
mPTP inhibitors in a rabbit cardiac ischaemia model
significantly limited infarct size to a comparable degree for
both pre- and PostC, thereby concluding that the protective
effect of PostC occurs through inhibition of the mPTP
opening.8 They also found that the Ca2þ load required to
open the mPTP in postconditioned rabbits was significantly
higher compared to controls, thereby demonstrating the
role of PostC in preservation of cell integrity by decreasing
the sensitivity of the mPTP to IRI-induced Ca2þ influx.
PostC-induced modulation of the mPTP opening possibly
occurs after 2 min of reperfusion as the pore opening is
inhibited prior to this by low pH under ischaemic
conditions.9
Inhibition of the mPTP opening is considered to be the
final step in a complex series of cellular signalling events
preventing cell death. It is thought that both pre- and PostC
activate a signal transduction pathway involving the pro-
survival kinases phosphatidylinositol-3-OH kinase (P13K)-Akt
and the p42/p44 extracellular signal-regulated kinases
(Erk1/2) which has been termed the reperfusion injury
salvage kinase (RISK) pathway. The RISK pathway terminates
with the inhibition of the mPTP opening at reperfusion to
afford cardioprotection in both IPC and PostC.10 This was
demonstrated pharmacologically by inhibiting ischaemic
PostC-induced phosphorylation of Akt, at the time of
reperfusion, abrogating PostC-induced cardioprotection in
rats.11 Fig. 1 shows a simplification of the key mechanisms
involved in achieving a reduction in cell death through PostC.Types of PostC e mechanical and pharmacological
Most of the animal studies, to date, relate to mechanical
PostC whereby cardiac ischaemia is induced by coronary
vessel occlusion, usually achieved by slinging the left
anterior descending artery, to mimic infarction. Reperfu-
sion is then stuttered as per protocol by releasing the vessel
slings for varying time periods. Optimal protocols are much
debated. In the initial description of PostC, a 44% reduction
in infarct size in canine myocardium was reported,
compared to the control group, using three cycles of 30 s of
alternating ischaemia/reperfusion (I/R) immediately
following an initial 60-min occlusion. This was consolidated
by a significant reduction in creatine kinase (CK) activity
and tissue oedema in the PostC group.1
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Figure 1 Simplification of the key mechanisms involved in achieving a reduction in cell death through postconditioning.
Potential for Future Application in Vascular Surgery 439As understanding of the mechanisms of PostC have been
unravelled, pharmacological PostC has arisen. Pharmaco-
logical PostC mimetics have the potential advantage of
reducing the requirement for invasive therapy associated
with unavoidable endothelial trauma and possible embolic
events, and some of them already have FDA approval
facilitating their usage in trials. Furthermore, they may
cater to a subset of patients too frail for invasive proce-
dures, or too far from specialised centres. FDA-approved
drugs such as adenosine12 and volatile anaesthetic agents
such as isoflurane13,14 and sevoflurane15 have already been
considered to improve outcome in animal studies.
Similar reductions in infarct size have been demon-
strated with isoflurane and mechanical or ischaemic PostC
in rabbit myocardium.16,17 In combination with mechanical
PostC, a cumulative beneficial effect has been shown.15
Anaesthetic-induced PostC appears to result from similar
mechanisms to ischaemic PostC, and the effect of both can
be abrogated by inhibition of the RISK pathway.17
Adenosine receptor stimulation has been implicated in
cardioprotection for some time, and its concentrations
have been found to be increased in the presence of
damaged tissue, suggesting a role for cellular protection.
For example, the results of the Acute Myocardial Infarction
Study of Adenosine (AMISTAD) trial I, prospectively
recruiting 236 patients, concluded that the addition of
adenosine to the treatment of acute myocardial infarction
(AMI) with thrombolysis resulted in a 33% reduction in
infarct size.18 Kin et al. found strong evidence to support
the involvement of some adenosine receptor subtypes in
PostC.19 They further demonstrated that PostC delays
washout of adenosine at 2 min, supporting the notion that
PostC is time related and significant delay results in loss of
this protective window. Adenosine has also been suggested
to be a trigger in the pathways involving survival kinases,
NO and KATP channels. Hausenloy and Yellon reviewed in
detail the host of other agents including cytokines; G-
protein-coupled receptor ligands, including bradykinin and
opioids, and statins such as atorvastatin20 thought to confercardioprotection in a similar manner, particularly through
activation of the RISK pathway.
Mechanical PostC e controversies from animal
studies
Since the initial description in canine models PostC has
been effective in multiple species and organ systems, but
debate still exists as to the optimal I/R cycle. The initial
assumption that more cycles of I/R would provide more
robust protection has now been discarded. Extending the
cumulative occlusion time not only causes aggravation of
the ischaemic insult, but multiple occlusive cycles may also
give rise to poor results due to vasospasm. For the same
reason, cycle duration is clearly important in influencing
the degree of PostC-induced protection. This logic did not
prevail in two studies on rabbits where three cycles of 20-s
I/Rs produced a reduction in the infarct size compared to
three cycles of 10-s I/Rs.16,17 Thus the implication arises
that there may be a minimum time threshold of ischaemia
in order to stimulate cardioprotection. This minimum time
threshold has so far not been reproducible between species
or even within species.
A similar predicament also exists regarding the time of
application of PostC after index ischaemia. A delay of
10 min before commencing PostC in rabbits resulted in
infarct sizes comparable with controls.21 A delay of just
1 min prior to onset of the cycle has been shown to reduce
the cardioprotection in rats.22 These findings suggest that
PostC acts to modulate IRI in the initial moments of
reperfusion.
The total duration of the index ischaemia also gives
variable results within the same species. Differing experi-
mental coronary occlusion times to produce index
ischaemia using the same PostC protocols have been found
to have different results. In some cases, just 30 min of
index ischaemia could be ameliorated, suggesting that
PostC is protective only after shorter episodes of index
ischaemia.23 A gender difference has been demonstrated in
440 K.A. Mockford et al.postconditioned rats, with female rat hearts not protected
after longer periods of index ischaemia in comparison to
their male counterparts.24 This may translate into humans,
driving a different optimal protocol for men and women.
Perhaps of most concern is the finding that PostC was
ineffective in hypercholesterolaemic rabbits.25 Whether
this study means that hypercholesterolaemic animals are
not protected by PostC or just that an effective protocol
was not trialled, this does potentially pose a problem for
clinical studies.
These controversies have obvious implications for
translation of this concept into human studies. A protocol
enrolling patients must be effective and safe for all
patients; multiple large trials may be required to identify
the optimum protocol for human studies and further for
individual organ systems.
Role of PostC in brain and spinal cord ischaemia
The protective effect of PostC in carotid artery occlusion
has been studied. Using anaesthetised rats, the middle
cerebral artery was cauterised and common carotid
arteries (CCAs) were occluded every 30 s for 10 s for a total
of three cycles. An 80%, 51% and 17% reductions in mean
infarct size were reported, with 15, 30 and 60 min of CCA
occlusions (index ischaemia), respectively, thereby indi-
cating the dependency of degree of protection afforded in
relation to the duration of index ischaemia.26 Unlike
cardiac tissue, the beneficial effect of PostC in the brain
tissue can be seen up to 2 days after the initial ischaemic
event. Danielisova et al. demonstrated the use of delayed
PostC to reverse impending neuronal death and reported
that it was effective when performed 2 days after the index
ischaemia with a staggering 90% reduction in neuronal
death.27 This delayed neuroprotection was, however, not
found in the spinal cord. Jiang et al. induced spinal cord
ischaemia in anaesthetised rabbits by cross-clamping the
abdominal aorta just distal to the renal arteries for 25 min.
They found that PostC initiated immediately after reper-
fusion produced significantly reduced neurological impair-
ment with improved hind limb motor function with less
protection at 5 min and no protection at 10 min.28 Although
the significance of PostC as a potential adjuvant treatment
in stroke, carotid endarterectomy and thoracic aortic
interventions cannot be underestimated, there is a paucity
of human data to propagate clinical relevance at this stage.
Human clinical trials
In 2005, Staat et al. published the first multicentre RCT
demonstrating that PostC is effective in humans. Thirty
patients with AMI underwent primary coronary angioplasty
and stenting, with 16 of 30 patients assigned to the PostC
arm of the trial. The protocol commenced within 1 min of
coronary stent insertion and comprised four cycles of 1-min
coronary artery I/R by angioplasty balloon. At 48 h post-
angioplasty, a significant reduction in mean ST-segment
elevation (PZ 0.09) and improved myocardial perfusion
(P< 0.02) were seen, followed by a significant reduction in
CK release (P< 0.05) during the first 72 h.7 Prolonged
protection by PostC has been demonstrated withPostC-induced reduction in infarct size in AMI remaining
apparent after 7 days of reperfusion.29 Ma et al., in 2006,
studied reactive oxygen species (ROS) production and
endothelial function in association with PostC in addition to
myocardial enzymes and cardiac function. They rando-
mised 94 patients with AMI undergoing primary coronary
angioplasty to control or PostC groups using three cycles of
30-s I/R. The postconditioned patients had a faster time to
normal blood flow in the infarct-related coronary artery
with a significantly (P< 0.05) lower CK and creatine kinase
isoenzyme (CK-MB) peaks. Wall motion score index was
significantly larger in the postconditioned group (P< 0.05),
corresponding with improved ventricular wall movement
post-angioplasty. Malondialdehyde (MDA) levels were
significantly lower in the postconditioned group (P< 0.05).
Brachial arterial endothelial function studied by echo
Doppler technique showed that endothelium-dependent
vasodilatory function was improved in the PostC group, but
there was no difference between the two groups with
regards to endothelium-independent function, thereby
indicating that PostC ameliorates endothelial dysfunction
probably via increased NO availability.30,31 Preservation of
endothelial function has also been demonstrated in
a separate study where this effect was lost even with
a 1-min delay post-reperfusion.32
In 2007, Luo et al. published the first RCT evaluating
PostC in surgical patients. They studied 24 children with
tetralogy of Fallot undergoing cardiac surgery. The PostC
group required significantly less inotropes during the first
24 h (PZ 0.017) and showed 50% lower troponin I
(PZ 0.05) and 34% lower CK-MB (PZ 0.034) levels than
controls.33 In 2008, they have reported a similar success in
adult valve replacement surgery randomising 50 patients
between control and PostC arms using three cycles of 30-s
aortic I/R.34
Successful pharmacological PostC in humans in the
surgical setting has been reported by Jin et al. using
1.5 mg kg1 adenosine given within 1 min of aortic cross-
clamp removal. A significant reduction in troponin and
reduced inotrope scores in patients undergoing valve
replacement surgery were noted.35 An improvement in
post-occlusive hyperaemic reaction of forearm endothe-
lium in the presence of sevoflurane has been shown.36Conclusion
PostC offers an exciting avenue for reducing the magnitude
of IRI, and its translation into clinical practice has been
demonstrated in the clinical setting. Further work is clearly
required to assess the potential benefit of PostC in humans,
particularly with respect to vascular surgery, and to stan-
dardise the protocols in relation to each organ system. It
does have an advantage over IPC in that forewarning of the
episode of index ischaemia is not required, although the
benefit of PostC may be limited by a delay in application
after reperfusion. The human data thus far are reported
only from myocardial studies, and there is clearly hetero-
geneity in the protocols used to gain this effect. PostC is
still very much limited to specialised centres and research
groups, and, until larger studies confirm its benefit, the
clinical results need to be scrutinised, and patients should
Potential for Future Application in Vascular Surgery 441be subjected to these treatments only after formal ethical
approval has been obtained.
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